Therapeutic strategies for treating osteolytic bone metastases

Autor: Jean-Claude Scimeca, Hugues Pascal-Mousselard, Heidy Schmid-Antomarchi, Jean-Michel Bouler, Annie Schmid-Alliana, Elise Verron
Přispěvatelé: Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation (CEISAM), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'ingénierie osteo-articulaire et dentaire (LIOAD), Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM)
Rok vydání: 2014
Předmět:
Oncology
Osteolysis
medicine.medical_treatment
Disease
0302 clinical medicine
Quality of life
[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]
Drug Discovery
Medicine
MESH: Animals
0303 health sciences
Bone Density Conservation Agents
Localized Cancer
Prognosis
MESH: Bone Neoplasms
3. Good health
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
030220 oncology & carcinogenesis
Systemic administration
MESH: Life Expectancy
medicine.medical_specialty
Antineoplastic Agents
Bone Neoplasms
[SDV.CAN]Life Sciences [q-bio]/Cancer
MESH: Prognosis
Bone resorption
MESH: Bone Density Conservation Agents
03 medical and health sciences
Life Expectancy
[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry
Molecular Biology/Genomics [q-bio.GN]

Internal medicine
Animals
Humans
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry
Molecular Biology/Biochemistry [q-bio.BM]

[SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/Biomaterials
030304 developmental biology
Pharmacology
MESH: Humans
business.industry
MESH: Quality of Life
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry
Molecular Biology/Molecular biology

medicine.disease
Surgery
Radiation therapy
Quality of Life
MESH: Antineoplastic Agents
MESH: Osteolysis
business
Zdroj: Drug Discovery Today Biosilico
Drug Discovery Today Biosilico, Elsevier, 2014, 19 (9), pp.1419-1426. ⟨10.1016/j.drudis.2014.04.004⟩
ISSN: 1359-6446
1741-8364
DOI: 10.1016/j.drudis.2014.04.004
Popis: International audience; The recent progress in oncologic management of patients with localized cancer or metastatic disease has permitted a significant improvement in life expectancy. Nevertheless, bone metastases and their consequent skeletal-related events (SREs) are still associated with unfavorable prognosis and greatly affect quality of life. Global management of these bone metastases includes traditional local approaches (surgery, radiotherapy, etc.) and systemic administration of chemotherapeutic agents. This review focuses on treatments specific for bone metastases and, in particular, on inhibitors of bone resorption that are effective for preventing and delaying the development of SREs.
Databáze: OpenAIRE